bpc-157 safety adverse effects humans case report Why would a patient trust a peptide more than a statin? FDA's Overreach on Compounded Peptides

While we understand the value of quality reporting data to the public, we believe that granting ECEs during certain circumstances where entire regions or locales may be experiencing a collective disruption in normal operations would alleviate some of the immediate administrative burden of submitting an ECE request

Although BPC 157 has shown promising results in preclinical studies, further research and clinical trials need to be done in order to determine its potential therapeutic application and safety in humans

If anything is unclear, your dispensing pharmacy can confirm the correct handling for your particular order

doi: 10.1007/978-3-319-22822-8_15 488 RichmanSMorrisMCBroderickGCraddockTJAKlimasNGFletcherMA